CGRP Inhibitors and Oxidative Stress Biomarkers in Resistant Migraine: A Real-Life Study with Erenumab, Fremanezumab, and Galcanezumab.

J Clin Med · 2021 · PMC8509234 · PMID 34640604

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

The latter exhibited an increasing trend at T1 (median 0.271μmol/L, IQR 0.062), T2 (0.276 μmol/L, IQR 0.071), and T3 (median 0.272 μmol/L, IQR 0.061) compared to T0 (median 0.235 μmol/L, IQR 0.0815), however without reaching statistical significance. 4.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.